I am an investor, founder, and author. I am also the managing partner of General Catalyst.
I am an early investor in market-leading companies like Stripe, Livongo (acquired by Teladoc in an $18.5B merger, the largest in digital health history to-date), Samsara (NYSE: IOT), Snap (NYSE: SNAP), Fundbox, Grammarly, Gusto, Applied Intuition, and Anduril.
I am an advocate for Responsible Innovation, aligning innovation with the long-term interests of society by engineering for growth and good with greater intention, fewer unintended consequences, and increased inclusivity. In my 2022 book Intended Consequences: How to Build Market-Leading Companies with Responsible Innovation, I lay out an actionable framework for founders and executives on how to create innovative companies built for growth and for societal good that withstand the test of time. As part of this, I am also co-founder and chairman of Responsible Innovation Labs, a non-profit consortium of leaders aiming to create standards of innovation to serve the needs of a global society, and to help build enduring companies that re-center technology as a force for good.
My 2020 book, UnHealthcare: A Manifesto for Health Assurance, co-authored with Dr. Stephen Klasko, CEO of Jefferson Health, details our thesis for how the healthcare system needs to transform a “sick care” system into a Health Assurance system designed to help people stay well, bend the cost curve, and make quality care more affordable and more accessible to all. In Unscaled, released in 2018, I articulate the need for accountability, transparency and explainability as AI permeates every aspect of our daily lives.
I wound up with five degrees from MIT because I was hoping to pursue an academic career: M.Eng. EECS, S.M. Operations Research, S.B. Biology, S.B. Mathematics, and S.B. EECS. In hindsight, that was excellent training for being a venture capitalist because I am always curious about new areas of innovation.
Alongside my work here at General Catalyst, I serve on the Stanford School of Medicine Board of Fellows, have worked on climate and energy issues as the co-founder and Chairman of Advanced Energy Economy, and I am a founding board member of Khan Lab School, an innovative K-12 school.
What is Hemant Taneja's net worth?
The estimated net worth of Hemant Taneja is at least $1.44 million as of April 19th, 2021. Dr. Taneja owns 142,560 shares of Teladoc Health stock worth more than $1,441,282 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Taneja may own. Learn More about Hemant Taneja's net worth.
How do I contact Hemant Taneja?
Has Hemant Taneja been buying or selling shares of Teladoc Health?
Hemant Taneja has not been actively trading shares of Teladoc Health in the last ninety days. Most recently, Hemant Taneja sold 25,000 shares of the business's stock in a transaction on Monday, April 19th. The shares were sold at an average price of $185.43, for a transaction totalling $4,635,750.00. Following the completion of the sale, the director now directly owns 142,560 shares of the company's stock, valued at $26,434,900.80. Learn More on Hemant Taneja's trading history.
Who are Teladoc Health's active insiders?
Teladoc Health's insider roster includes Michelle Bucaria (Insider), Karen Daniel (Director), Sandra Fenwick (Director), William Frist (Director), Arnnon Geshuri (Insider), Jason Gorevic (CEO), Claus Jensen (Insider), Laizer Kornwasser (President, Enterprise Growth and Global Markets), Lewis Levy (Insider), Mala Murthy (CFO), Richard Napolitano (CAO), Kenneth Paulus (Director), Vidya Raman-Tangella (Insider), David Shedlarz (Director), David Sides (COO), Hemant Taneja (Director), Daniel Trencher (SVP), Andrew Turitz (SVP), Adam Vandervoort (Insider), Stephany Verstraete (CMO), Yulun Wang (Insider), and Michael Waters (COO). Learn More on Teladoc Health's active insiders.
Are insiders buying or selling shares of Teladoc Health?
During the last year, Teladoc Health insiders bought shares 2 times. They purchased a total of 11,000 shares worth more than $83,750.00. During the last year, insiders at the health services provider sold shares 38 times. They sold a total of 266,139 shares worth more than $3,768,176.90. The most recent insider tranaction occured on September, 12th when Director Thomas Mckinley bought 4,000 shares worth more than $30,760.00. Insiders at Teladoc Health own 1.0% of the company.
Learn More about insider trades at Teladoc Health. Information on this page was last updated on 9/12/2024.
